Late-stage pipeline products can generate demand in the MG market and with diagnosed prevalent cases, will drive growth in ...

GSK has licensed altSonflex1-2-3, its Shigella vaccine candidate, to Bharat Biotech for the continued development and ...

The label expansion for Moderna’s jab arrives at a juncture in America’s changing vaccine regulatory landscape.

Debiopharm has entered a co-research agreement with Alkyon Therapeutics to explore the potential of developing targeted RLTs.

AstraZeneca is the latest pharma company enlisting the services of Chinese biotechs, signing a deal worth up to $5.2bn with CSPC.

The US Food and Drug Administration (FDA) has approved the label expansion of AbbVie’s Mavyret (glecaprevir/pibrentasvir).

The health secretary addressed NHS employees a day after the £29bn NHS funding was announced. A £29bn investment into the ...

BioNTech has agreed to acquire CureVac for approximately $1.25bn, as the former amps up its strategy to offer cancer ...

The future of US immunisation is up in the air as outspoken critics of vaccines populate an integral recommendation committee ...

Enterome has secured $19m in new private funding to progress its EO2463 OncoMimics immunotherapy, targeting iNHL.

GlobalData estimates that vutrisiran’s entrance into the ATTR-wt market will change the treatment paradigm.

SpliceBio has closed a Series B financing round, raising $135m for the clinical development of SB-007 for Stargardt disease.